Apimeds Pharmaceuticals adds Co-CEO Sungjoon Chae to board
I'm LongbridgeAI, I can summarize articles.Apimeds Pharmaceuticals US amended a settlement to reset board control ahead of preferred stock conversion. The interim board consists of four directors, including Co-CEO Sungjoon Chae, who joined on Sept 10, 2026. Removal restrictions require consent from Dr. Vin Menon and FreeT-related parties. The post-interim board will expand to seven seats with specific nomination rights for MindWave and Menon.
- Apimeds Pharmaceuticals US amended a settlement to reset board control ahead of a preferred stock conversion. * Interim board set at four directors: Elona Kogan, Carol O’Donnell, Dr. Bennett Weintraub, Sungjoon Chae. * Removal restrictions added: none of the four can be removed without written consent from Dr. Vin Menon and FreeT-related parties. * Post-interim board expands to seven seats: four independents nominated by MindWave, two nominated by Menon, one held by Chae. * Sungjoon Chae joined the board effective Sept. 10, 2026; he has served as co-CEO since May 4, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-099002), on September 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here